PBLS
Parabilis Medicines, Inc.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Sell
-47/100
Last price
28.86
▼ 0.67 (2.27%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
29.53
Day high
29.73
Day low
28.17
Volume
979.20K
Market cap
$3.57B
P/E (TTM)
—
52W range
24.51 – 42.49
Trailing performance
Returnvs SPY
1W
-9.56%
-11.5%
1M
-28.60%
-29.8%
3M
-6.39%
-10.9%
6M
—
-18.2%
YTD
-8.67%
-22.9%
1Y
—
-16.4%
3Y
—
-82.3%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on PBLS open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
8.68M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Jul 22, 26 | RA CAPITAL MANAGEMENT, L.P. Beneficial Owner of more than 10% of a Class of Security |
BUY | 244.59K | $6.92M | Indirect |
| Jun 15, 26 | SEBULSKY ALAN M Director |
BUY | 17.50K | $473.53K | Indirect |
| Jun 11, 26 | SEBULSKY ALAN M Director |
BUY | 12.50K | $378.88K | Indirect |
| Jun 11, 26 | FLYNN JAMES E Beneficial Owner of more than 10% of a Class of Security |
— | 1.88M | — | Indirect |
| Jun 11, 26 | FITZGERALD EDWARD M Director |
— | 14.69K | — | Direct |
| Jun 11, 26 | BORISY ALEXIS Director |
— | 105.41K | — | Direct |
| Jun 11, 26 | RA CAPITAL MANAGEMENT, L.P. Beneficial Owner of more than 10% of a Class of Security |
BUY | 21.19M | $642.23M | Indirect |
| Jun 11, 26 | RA CAPITAL MANAGEMENT, L.P. Beneficial Owner of more than 10% of a Class of Security |
— | 7.74M | — | Indirect |
| Jun 11, 26 | LEVY GUY B Beneficial Owner of more than 10% of a Class of Security |
BUY | 500.00K | $15.15M | Indirect |
| Jun 11, 26 | LEVY GUY B Beneficial Owner of more than 10% of a Class of Security |
CONVERSION | 527.07K | $5.00M | Indirect |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BORISY ALEXIS |
Director | 105.41K | Conversion of Exercise of derivative security |
FITZGERALD EDWARD M |
Director | 14.69K | Conversion of Exercise of derivative security |
FLYNN JAMES E |
Beneficial Owner of more than 10% of a Class of Security | — | Conversion of Exercise of derivative security |
LEVY GUY B |
Beneficial Owner of more than 10% of a Class of Security | — | Purchase |
RA CAPITAL MANAGEMENT, L.P. |
Beneficial Owner of more than 10% of a Class of Security | — | Purchase |
SEBULSKY ALAN M |
Director | — | Purchase |
Fundamentals
Market cap$3.57B
Enterprise value$2.49B
Revenue (TTM)$148.00K
Gross profit$-12.95M
EBITDA$-169.11M
Net income$-231.67M
EPS (TTM)$-9.51
Free cash flow—
Total cash$1.12B
Total debt$47.51M
Book value / share$8.48
Shares outstanding121.95M
Float82.07M
Short % of float5.00%
Dividend yield0.00%
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E-13.20
PEG ratio—
Price / sales—
Price / book3.40
EV / revenue16,837.73
EV / EBITDA-14.74
Gross margin0.00%
Operating margin-34382.43%
Profit margin0.00%
Return on equity—
Return on assets—
Debt / equity4.54
Current ratio17.91
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | YoY |
|---|---|---|---|
| Total revenue | $0 | $0 | — |
| Operating revenue | $0 | $0 | — |
| Research & development | $125.58M | $100.83M | +24.6% |
| Selling, general & admin | $26.50M | $25.30M | +4.7% |
| Total operating expense | $152.08M | $126.13M | +20.6% |
| Operating income | -$152.08M | -$126.13M | -20.6% |
| Net interest income | $1.86M | $4.92M | -62.1% |
| Pre-tax income | -$145.89M | -$117.91M | -23.7% |
| Net income | -$145.89M | -$117.91M | -23.7% |
| Net income to common | -$186.93M | -$161.48M | -15.8% |
| Basic EPS | -1.81 | -2.01 | +9.9% |
| Diluted EPS | -1.81 | -2.01 | +9.9% |
| EBIT | -$144.37M | -$116.43M | -24.0% |
| EBITDA | -$141.87M | -$114.33M | -24.1% |
| Basic shares | 80.37M | 80.40M | -0.0% |
| Diluted shares | 80.37M | 80.40M | -0.0% |
| Line item | 2025 | 2024 | YoY |
|---|---|---|---|
| Cash & equivalents | $27.71M | $47.28M | -41.4% |
| Cash & short-term investments | $27.71M | $87.98M | -68.5% |
| Total current assets | $29.36M | $92.21M | -68.2% |
| Property, plant & equipment | $46.08M | $52.93M | -12.9% |
| Total assets | $80.82M | $149.25M | -45.9% |
| Total current liabilities | $56.79M | $32.41M | +75.2% |
| Current debt | $13.08M | $2.50M | +423.1% |
| Long-term debt | — | $12.79M | — |
| Total debt | $58.70M | $66.20M | -11.3% |
| Total liabilities | $97.34M | $92.81M | +4.9% |
| Retained earnings | -$541.50M | -$395.62M | -36.9% |
| Shareholder equity | -$16.52M | $56.44M | -129.3% |
| Working capital | -$27.43M | $59.80M | -145.9% |
| Net tangible assets | -$16.52M | $56.44M | -129.3% |
| Shares issued | 118.15M | 118.15M | 0.0% |
| Line item | 2025 | 2024 | YoY |
|---|---|---|---|
| Net income | -$145.89M | -$117.91M | -23.7% |
| Depreciation & amortisation | $2.50M | $2.10M | +19.0% |
| Stock-based compensation | $3.32M | $4.31M | -23.0% |
| Change in working capital | $9.12M | $910.00K | +901.9% |
| Operating cash flow | -$123.71M | -$103.61M | -19.4% |
| Capital expenditure | -$306.00K | -$879.00K | +65.2% |
| Investing cash flow | $39.76M | $30.24M | +31.5% |
| Share buybacks | -$62.00K | -$494.00K | +87.4% |
| Financing cash flow | $64.38M | $78.07M | -17.5% |
| Free cash flow | -$124.02M | -$104.49M | -18.7% |
| End cash position | $30.57M | $50.14M | -39.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|
| Total revenue | $148.00K | $0 | $0 | $0 | — |
| Operating revenue | $148.00K | $0 | $0 | $0 | — |
| Research & development | $39.38M | $37.75M | $30.13M | $33.91M | +4.3% |
| Selling, general & admin | $11.66M | $9.70M | $6.39M | $6.34M | +20.2% |
| Total operating expense | $51.03M | $47.45M | $36.52M | $40.24M | +7.5% |
| Operating income | -$50.89M | -$47.45M | -$36.52M | -$40.24M | -7.2% |
| Net interest income | $3.98M | $2.14M | $653.00K | $858.00K | +86.2% |
| Pre-tax income | -$52.46M | -$45.32M | -$34.81M | -$38.33M | -15.8% |
| Net income | -$52.46M | -$45.32M | -$34.81M | -$38.33M | -15.8% |
| Net income to common | -$66.95M | -$70.88M | -$44.99M | -$48.11M | +5.5% |
| Basic EPS | -0.54 | -0.56 | -0.56 | -0.60 | +3.2% |
| Diluted EPS | -0.54 | -0.56 | -0.56 | -0.60 | +3.2% |
| EBIT | -$52.25M | -$45.02M | -$34.41M | -$37.93M | -16.1% |
| EBITDA | -$51.66M | -$44.42M | -$33.80M | -$37.27M | -16.3% |
| Basic shares | 123.52M | 80.40M | 80.40M | 80.40M | +53.6% |
| Diluted shares | 123.52M | 80.40M | 80.40M | 80.40M | +53.6% |
| Line item | 2026-06-30 | 2026-03-31 | YoY |
|---|---|---|---|
| Cash & equivalents | $1.09B | $329.04M | +230.4% |
| Cash & short-term investments | $1.12B | $329.04M | +240.6% |
| Total current assets | $1.13B | $332.07M | +238.9% |
| Property, plant & equipment | $42.73M | $44.35M | -3.7% |
| Total assets | $1.18B | $384.17M | +205.9% |
| Total current liabilities | $62.84M | $54.24M | +15.9% |
| Current debt | $5.71M | $9.40M | -39.3% |
| Total debt | $47.51M | $53.15M | -10.6% |
| Total liabilities | $127.53M | $139.95M | -8.9% |
| Retained earnings | -$639.28M | -$586.82M | -8.9% |
| Shareholder equity | $1.05B | $244.22M | +329.0% |
| Working capital | $1.06B | $277.83M | +282.4% |
| Net tangible assets | $1.05B | $244.22M | +329.0% |
| Shares issued | 123.52M | 118.15M | +4.5% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|
| Net income | -$52.46M | -$45.32M | -$34.81M | -$38.33M | -15.8% |
| Depreciation & amortisation | $593.00K | $606.00K | $618.00K | $654.00K | -2.1% |
| Stock-based compensation | $3.63M | $1.30M | $823.00K | $852.00K | +178.7% |
| Change in working capital | $37.52M | -$7.53M | $370.00K | $871.00K | +598.2% |
| Operating cash flow | -$3.62M | -$49.20M | -$31.09M | -$34.15M | +92.6% |
| Capital expenditure | -$616.00K | -$369.00K | -$16.00K | -$74.00K | -66.9% |
| Investing cash flow | -$34.06M | -$369.00K | $24.51M | $6.69M | -9,131.2% |
| Financing cash flow | $795.71M | $350.90M | -$135.00K | $67.29M | +126.8% |
| Free cash flow | -$4.24M | -$49.57M | -$31.11M | -$34.23M | +91.5% |
| End cash position | $1.09B | $331.89M | $83.25M | $89.96M | +228.4% |
Options analytics
Put / call volume
1.12
Put-heavy session
Put / call open interest
—
Positioning, not flow
Max pain
25.00
-13.4% from spot
ATM implied vol
6.3%
Nearest strike to spot
Skew (10% OTM)
+18.7%
Puts bid over calls
Call volume
17
Contracts, this expiry
Put volume
19
Contracts, this expiry
Heaviest call OI
30.00
0 contracts
Heaviest put OI
25.00
0 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.24 | -2.12 | -772.9% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.38 | 3 | $500.00K | — |
| Next quarter | -0.40 | 3 | $1.00M | — |
| Current year | -2.58 | 3 | $1.03M | — |
| Next year | -2.19 | 3 | $3.33M | +222.6% |
Analyst targets & ownership
Mean target$41.75
High target$45.00
Low target$40.00
Implied upside44.66%
Analyst count4
ConsensusNONE
Strong buy / Buy0 / 5
Hold0
Sell / Strong sell0 / 0
Held by insiders7.03%
Held by institutions82.26%
Institutions holding94
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
31.29
-7.75% from price
SMA 20
34.56
-16.50% from price
SMA 50
36.21
-20.30% from price
SMA 100
—
—
SMA 200
—
—
EMA 12
32.14
-10.20% from price
EMA 26
34.20
-15.60% from price
EMA 50
34.18
-15.56% from price
RSI (14)
32.9
Neutral
MACD (12,26,9)
-2.06
Hist -0.77
ATR (14)
3.35
11.61% of price
Realised vol 30D
71.2%
Annualised
Bollinger upper
41.94
20, 2σ
Bollinger lower
27.19
20, 2σ
50 / 200 cross
—
—
Trend bias
—
—
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
-0.54
Less volatile than market
Correlation to SPY
-0.09
Largely independent
Realised vol 30D
71.2%
Annualised
Market vol 1Y
11.9%
SPY, annualised
Max drawdown 1Y
-30.8%
Peak to trough
Max drawdown 5Y
-30.8%
Peak to trough
ATR 14
3.35
11.61% of price
Beta (reported)
—
5Y monthly, from filing
Short interest
Shares short
6.09M
Prior 5.26M
Change vs prior
+15.9%
Shorts adding
% of float
5.00%
Normal
% of shares out
4.93%
Against total outstanding
Days to cover
14.2
Crowded exit
Float
82.07M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jul 6, 26 | Guggenheim | INITIATED | — | Buy |
| Jul 6, 26 | Leerink Partners | INITIATED | — | Outperform |
| Jul 6, 26 | B of A Securities | INITIATED | — | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-09-15
Corporate Changes & Voting Matters
8-K · 2026-09-02
Corporate Changes & Voting Matters
8-K · 2026-08-25
Periodic Financial Reports
10-Q · 2026-08-13
Corporate Changes & Voting Matters
8-K · 2026-06-11
Offering Registrations
S-8 · 2026-06-10
Offering Registrations
S-1MEF · 2026-06-09
Trading Registrations
8-A12B · 2026-06-05
Headlines
Sixty Degree Capital Extends Its Track Record as Five Portfolio Companies Enter the Public Markets in 2026
CNW Group · 9d ago
Sixty Degree Capital Extends Its Track Record as Five Portfolio Companies Enter the Public Markets in 2026
PR Newswire · 9d ago
MeiraGTx Appoints Accomplished Healthcare Portfolio Manager Alan M. Sebulsky to Board of Directors
GlobeNewswire · 14d ago
Parabilis Medicines to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
GlobeNewswire · 36d ago
Parabilis Medicines Appoints Accomplished Drug Development Leader Craig L. Tendler, M.D., to Board of Directors
GlobeNewswire · 43d ago
Young startups miss out on biotech venture funding rebound, MassBio says
BioPharma Dive · 43d ago
Parabilis Medicines Q2 Loss Narrows; Shares Rise Pre-Bell
MT Newswires · 55d ago
Parabilis Medicines: Q2 Earnings Snapshot
Associated Press · 55d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.